Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

The selective vasopressin V2–receptor antagonist tolvaptan is eliminated almost exclusively by non-renal mechanisms. As renal impairment can influence the pharmacokinetics of drugs even when eliminated by non-renal mechanisms, we evaluated the effect of renal insufficiency on the pharmacokinetics/ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoaf, Susan E, Bricmont, Patricia, Mallikaarjun, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973039/
https://www.ncbi.nlm.nih.gov/pubmed/24048380
http://dx.doi.org/10.1038/ki.2013.350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973039/
https://www.ncbi.nlm.nih.gov/pubmed/24048380
http://dx.doi.org/10.1038/ki.2013.350

Ejemplares similares